Cutting edge: Intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcγRIIIA-dependent mechanisms

Journal of Immunology

Volumn 186, Issue 6, 2011, Pages 3289-3293

  Araujo, Luiza M ^a,b   Chauvineau, Angélique ^c,d,e   Zhu, Ren ^a,b   Diem, Séverine ^a,b   Bourgeois, Elvire A ^a,d,f   Levescot, Anaïs ^a,d,f   Huerre, Michel ^g   Gombert, Jean Marc ^c,d,e   Bayry, Jagadeesh ^b,h,i   Daëron, Marc ^g,j   Bruhns, Pierre ^g,j   Kaveri, Srini V ^b,h,i   Herbelin, André ^a,d,f,k  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e UNIVERSITÉ DE POITIERS   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSTITUT PASTEUR   (France)

^h CENTRE DE RECHERCHE DES CORDELIERS   (France)

ⁱ INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^j INSERM   (France)

^k Centre National de la Recherche Scientifique   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIIA; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; LYMPHOCYTE FUNCTION; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ALLERGENS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHIAL HYPERREACTIVITY; CYTOKINES; GALACTOSYLCERAMIDES; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; OVALBUMIN; RECEPTORS, IGG; RESPIRATORY HYPERSENSITIVITY; SPLEEN;

EID: 79953202496     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003076     Document Type: Article

References (36)

1. Nimmerjahn, F., and J. V. Ravetch. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26: 513-533.
2. Tha-In, T., J. Bayry, H. J. Metselaar, S. V. Kaveri, and J. Kwekkeboom. 2008. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29: 608-615.
3. Kazatchkine, M. D., and S. V. Kaveri. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
4. Mazer, B. D., and E. W. Gelfand. 1991. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J. Allergy Clin. Immunol. 87: 976-983.
5. Sapir, T., M. Blank, and Y. Shoenfeld. 2005. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann. N. Y. Acad. Sci. 1051: 743-778.
6. Gold, R., M. Stangel, and M. C. Dalakas. 2007. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3: 36-44.
7. Sherer, Y., Y. Levy, F. Fabrizzi, and Y. Shoenfeld. 1999. Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Barc) 35: 513-518. (Pubitemid 29422127)
8. Bruhns, P., A. Samuelsson, J. W. Pollard, and J. V. Ravetch. 2003. Colony-timulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18: 573-581.
9. Akilesh, S., S. Petkova, T. J. Sproule, D. J. Shaffer, G. J. Christianson, and D. Roopenian. 2004. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113: 1328-1333.
10. Siragam, V., A. R. Crow, D. Brinc, S. Song, J. Freedman, and A. H. Lazarus. 2006. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med. 12: 688-692.
11. Paquin Proulx, D., E. Aubin, R. Lemieux, and R. Bazin. 2010. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin. Immunol. 135: 422-429.
12. von Gunten, S., and H. U. Simon. 2008. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun. Rev. 7: 453-456.
13. Vani, J., S. Elluru, V. S. Negi, S. Lacroix-Desmazes, M. D. Kazatchkine, J. Bayary, and S. V. Kaveri. 2008. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun. Rev. 7: 440-444.
14. Seite, J. F., Y. Shoenfeld, P. Youinou, and S. Hillion. 2008. What is the contents of the magic draft IVIg? Autoimmun. Rev. 7: 435-439.
15. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629. (Pubitemid 27516282)
16. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
17. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu, III, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529. (Pubitemid 40477062)
18. Akbari, O., P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M. J. Grusby, R. H. DeKruyff, and D. T. Umetsu. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9: 582-588.
19. Zhu, R., S. Diem, L. M. Araujo, A. Aumeunier, J. Denizeau, E. Philadelphe, D. Damotte, M. Samson, P. Gourdy, M. Dy, et al. 2007. The Pro-Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis. J. Immunol. 178: 5435-5442. (Pubitemid 46674337)
20. Bourgeois, E., L. P. Van, M. Samson, S. Diem, A. Barra, S. Roga, J. M. Gombert, E. Schneider, M. Dy, P. Gourdy, et al. 2009. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur. J. Immunol. 39: 1046-1055.
21. Lisbonne, M., and M. C. Leite-de-Moraes. 2003. Invariant Valpha14 NKT lymphocytes: a double-edged immuno-regulatory T cell population. Eur. Cytokine Netw. 14: 4-14.
22. Wilson, S. B., and T. L. Delovitch. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3: 211-222.
23. Mars, L. T., J. Novak, R. S. Liblau, and A. Lehuen. 2004. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol. 25: 471-476. (Pubitemid 39490253)
24. Lisbonne, M., S. Diem, A. de Castro Keller, J. Lefort, L. M. Araujo, P. Hachem, J. M. Fourneau, S. Sidobre, M. Kronenberg, M. Taniguchi, et al. 2003. Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171: 1637-1641. (Pubitemid 36966444)
25. Araujo, L. M., J. Lefort, M. A. Nahori, S. Diem, R. Zhu, M. Dy, M. C. Leite-de-Moraes, J. F. Bach, B. B. Vargaftig, and A. Herbelin. 2004. Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells. Eur. J. Immunol. 34: 327-335.
26. Beasley, R. 2002. The burden of asthma with specific reference to the United States. J. Allergy Clin. Immunol. 109(5, Suppl): S482-S489.
27. Weiss, K. B., and S. D. Sullivan. 2001. The health economics of asthma and rhinitis. I. Assessing the economic impact. J. Allergy Clin. Immunol. 107: 3-8.
28. Wills-Karp, M. 1999. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17: 255-281.
29. Orange, J. S., E. M. Hossny, C. R. Weiler, M. Ballow, M. Berger, F. A. Bonilla, R. Buckley, J. Chinen, Y. El-Gamal, B. D. Mazer, et al; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. 2006. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. [Published erratum appears in 2006. J. Allergy Clin. Immunol. 117: 1483.] J. Allergy Clin. Immunol. 117(4, Suppl): S525-S553.
30. Schwartz, H. J., R. W. Hostoffer, E. R. McFadden, Jr., and M. Berger. 2006. The response to intravenous immunoglobulin replacement therapy in patients with asthma with specific antibody deficiency. Allergy Asthma Proc. 27: 53-58. (Pubitemid 43440066)
31. Hachem, P., M. Lisbonne, M. L. Michel, S. Diem, S. Roongapinun, J. Lefort, G. Marchal, A. Herbelin, P. W. Askenase, M. Dy, and M. C. Leite-de-Moraes. 2005. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. Eur. J. Immunol. 35: 2793-2802.
32. Morishima, Y., Y. Ishii, T. Kimura, A. Shibuya, K. Shibuya, A. E. Hegab, T. Iizuka, T. Kiwamoto, Y. Matsuno, T. Sakamoto, et al. 2005. Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. Eur. J. Immunol. 35: 2803-2814.
33. Kim, H. Y., S. Kim, and D. H. Chung. 2006. FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J. Clin. Invest. 116: 2484-2492.
34. Amigorena, S., C. Bonnerot, J. R. Drake, D. Choquet, W. Hunziker, J. G. Guillet, P. Webster, C. Sautes, I. Mellman, and W. H. Fridman. 1992. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256: 1808-1812.
35. Park-Min, K. H., N. V. Serbina, W. Yang, X. Ma, G. Krystal, B. G. Neel, S. L. Nutt, X. Hu, and L. B. Ivashkiv. 2007. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26: 67-78.
36. Clynes, R. 2007. IVIG therapy: interfering with interferon-gamma. Immunity 26: 4-6.